NCT06478719View on ClinicalTrials.gov

To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

June 7, 2027

Study Completion Date

August 6, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Placebo

Placebo oral capsule

DRUG

FB-1603

FB-1603 (165 mg/cap) oral capsule

Trial Locations (1)

10002

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

lead

Febico Biomedical Corp.

INDUSTRY